Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the e... Hemispherx Biopharma Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States. 詳細を表示
OCALA, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat...
OCALA, Fla., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
OCALA, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report...
OCALA, Fla., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI...
OCALA, Fla., June 28, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB) announced today that Adam Pascale is retiring from the position of Chief Financial Officer after...
OCALA, Fla., June 17, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. (NYSE American: HEB) issued its quarterly update on the progress of its ongoing clinical trials evaluating Ampligen’s...
OCALA, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- (NYSE American: HEB) — Hemispherx Biopharma Inc. announced today that the first patient has been treated in the Phase 2 recurrent ovarian cancer...
OCALA, Fla., May 31, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
OCALA Fla., May 16, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple...
ORLANDO, FL, May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Hemispherx Biopharma Inc., (NYSE American: HEB), an immuno-pharma company focused on the research and development of...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 銘柄コード | 株価 | 出来高 |
|---|---|---|
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 33.341 (11.81%) | 34.81M |
| SBEVSplash Beverage Group Inc | US$ 0.28 (16.76%) | 33.65M |
| RHERegional Health Properties Inc | US$ 4.88 (214.84%) | 30.68M |
| AEONAEON Biopharma Inc | US$ 0.1732 (-69.56%) | 29.14M |
| SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 18.0401 (-11.61%) | 22.18M |
mick
4年前
Richard2
4年前
mick
5年前
deniseann
5年前
Richard2
5年前
Richard2
5年前
deniseann
5年前
lowfloatwayne
5年前
Richard2
5年前
LW89
5年前
lowfloatwayne
5年前
lowfloatwayne
5年前
cspratt15139
5年前
lowfloatwayne
5年前
cspratt15139
5年前
lowfloatwayne
5年前
aristotelisonassis
5年前
cspratt15139
6年前
cspratt15139
6年前
bleu22
6年前
cspratt15139
6年前
420man
6年前
bleu22
6年前
whytestocks
6年前
420man
6年前
cspratt15139
6年前
420man
6年前
Golden Cross
6年前
whytestocks
6年前
cspratt15139
6年前
hebbeke47
6年前
carldfw
6年前
Golden Cross
6年前
whytestocks
6年前
Golden Cross
6年前
tknuncle
6年前
420man
6年前
pberger
6年前
ClayTrader
6年前
Golden Cross
6年前
nokomis
6年前
pberger
6年前
Golden Cross
6年前
ClayTrader
6年前
Golden Cross
6年前
Zarate69
6年前
tknuncle
6年前
aidytrader
6年前
TommyBoyTrader9460
6年前
JJGl
6年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
